0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Ideas and Opinions |

Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection

Vicky Baffis, MD, FRCP(C); Ian Shrier, MD, PhD; Averell H. Sherker, MD, FRCP(C); and Andrew Szilagyi, MD, FRCP(C)
[+] Article and Author Information

From Sir Mortimer B. Davis-Jewish General Hospital and McGill University, Montreal, Quebec, Canada.


Requests for Reprints: Andrew Szilagyi, MD, FRCP(C), 6000 Côte-des-Neiges, Suite 100, Montreal, Quebec H3S 1Z8, Canada; e-mail, asherker@gas.jgh.mcgill.ca. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints@mail.acponline.org.

Current Author Addresses: Dr. Baffis: McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.

Drs. Shrier and Sherker: Sir Mortimer B. Davis-Jewish General Hospital, 3755 Côte-Ste-Catherine, Montreal, Quebec H3T 1E2, Canada.

Dr. Szilagyi: 6000 Côte-des-Neiges, Suite 100, Montreal, Quebec H3S 1Z8, Canada.


Ann Intern Med. 1999;131(9):696-701. doi:10.7326/0003-4819-131-9-199911020-00011
Text Size: A A A

The incidence of hepatocellular carcinoma in North America is increasing. Current debate focuses on whether interferon administered to cirrhotic patients—with or without biochemical or virologic response—delays or prevents cancer of the liver. Review of the literature revealed several studies that showed improvement in or delay in progression of histologic fibrosis in patients with hepatitis C virus (HCV) infection. In patients with hepatitis B virus (HBV) infection, conversion to the nonreplicative stage may be associated with histologic improvement. However, only 11 studies (6 of HCV, 3 of HBV, and 2 of HCV and HBV) compared development of hepatocellular carcinoma in interferon-treated patients with cirrhosis and cirrhotic patients who were not treated with interferon. Although no firm statistical conclusions could be drawn, the literature suggests that interferon therapy may prevent hepatocellular carcinoma in patients with cirrhosis, particularly those infected with HCV.

Interferon treatment cannot be recommended for all persons with cirrhosis and HBV or HCV infection because the current evidence is only suggestive. Long-term randomized, controlled trials may provide definitive data; however, it will be difficult, if not impossible, to conduct such trials because of the improved efficacy of combination therapy with interferon and ribavirin in patients with chronic HCV infection and the development of new therapies for patients with HBV infection.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Hepatitis C viral infection among prisoners. Vojnosanit Pregl 2013;70(11):1006-9.
Antiviral treatment of hepatitis C. BMJ 2014;348():g3308.
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)